Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03806218 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

RFA Using Dual Cooled-wet Electrode for Treatment of Recurrent HCC After Locoregional Treatment

Start date: May 16, 2015
Phase: N/A
Study type: Interventional

This study was conducted to provide preliminary data for the main trial to compare efficacy between switching bipolar radiofrequency ablation (RFA) using dual internally cooled-wet electrodes and switching monopolar RFA using separable clustered electrodes in the treatment of recurrent hepatocellular carcinoma (HCC) after locoregional treatment.

NCT ID: NCT03699657 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Dual and Single Switching Monopolar RFA Using Octopus Electrodes for Treatment of HCC

Start date: December 15, 2014
Phase: N/A
Study type: Interventional

This study was conducted to prospectively compare the efficacy, safety and mid-term outcomes of dual-switching monopolar (DSM) radiofrequency ablation (RFA) with those of conventional single-switching monopolar (SSM) RFA in the treatment of hepatocellular carcinoma (HCC).

NCT ID: NCT03463876 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

Start date: February 5, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.

NCT ID: NCT03380130 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC

NASIR-HCC
Start date: September 11, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of the anti-programmed death 1 (PD-1) agent nivolumab following selective internal radiation therapy (SIRT) for patients with unresectable hepatocellular carcinoma (HCC). SIRT using yttrium90-loaded microspheres is increasingly used to treat patients with HCC, particularly those that are not good candidates for transarterial chemoembolization or TACE. SIRT induces disease control (objective tumor remission or stabilization) in most patients while progression usually results from the growth of new lesions. SIR-Spheres are resin-made microspheres used for SIRT. On the other hand, nivolumab is under clinical development for the treatment of more advanced HCC. Available data in patients that mostly had progression to other therapies and vascular involvement or metastatic disease show significant systemic antitumor activity that results in durable objective remissions and disease stabilizations. Therefore, in patients with HCC that has not spread beyond the liver, the systemic action of nivolumab may improve the anti-tumor effect of SIRT. Furthermore, by inducing immunogenic tumor cell death, SIRT may have a synergistic effect with nivolumab.

NCT ID: NCT03212625 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction

Start date: January 28, 2016
Phase: Phase 4
Study type: Interventional

Many investigators have studied for prevention and care of Hand-Foot Skin Reaction(HFSR), and urea cream is typical representative. Recent study was performed prevention effect of urea cream for Hand-Foot Skin Reaction(HFSR) on 871 Chinese. But the study did not designed as placebo-control group and it had big defect in double-blinded. Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect of urea cream on Korean patient group.

NCT ID: NCT03158818 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Chronic Hepatitis B Virus Infection in Zambia

HUTCH
Start date: August 23, 2016
Phase:
Study type: Observational

Chronic hepatitis B virus infection is a common condition in Zambia. Among Zambian blood donors, up to 8% are chronically infected with HBV. Despite the burden, awareness of HBV is low in Zambia and the Ministry of Health is in early stages of development of guidelines for HBV screening, treatment, and prevention. The purpose of this clinical cohort study is to characterize the clinical features of chronic HBV infection at UTH and describe treatment and care outcomes. The investigators will enroll 500 adults and follow the cohort for up to 5 years to assess short and long-term viral, serologic, and liver outcomes such as cirrhosis and liver cancer.

NCT ID: NCT03116945 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Novel Gallium Imaging in Hepatocellular Carcinoma

Start date: June 2016
Phase: Phase 2
Study type: Interventional

The aim of the present study is to validate the uptake of novel, positron emitting radiotracer, 68Gallium Citrate in hepatocellular carcinoma(HCC). The investigators also aim to evaluate the sensitivity of 68Gallium (68Ga)-citrate positron emission tomography/computed tomography (PET/CT) for the identification of intrahepatic HCC lesions in comparison with existing modalities: computed tomography (CT) alone and magnetic resonance imaging (MRI). The investigators expect that 68Ga-citrate PET/CT will offer a sensitive functional imaging modality for identification of HCC lesions in the liver. The investigators intend to use the results of this preliminary study to fuel further studies in the utility of 68Ga-citrate PET/CT for HCC treatment monitoring.

NCT ID: NCT03109886 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma

Start date: July 12, 2017
Phase: Phase 2
Study type: Interventional

The primary aim of this exploratory study is to test the safety and tolerability of milciclib when administered orally at 100 mg in patients with recurrent or metastatic Hepatocellular Carcinoma. The evaluation of the efficacy profile is a secondary objective of the study. Moreover, markers expression in tumor cells and plasma will be studied and described in association with the clinical outcome. Eligible patients will receive milciclib orally on a daily schedule for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. At the end of Cycle 3, treatment will be stopped, and based on the results of the tumor assessment performed on Day 90 (±3 days) from treatment start, patients will be followed as here below detailed: - patients with Complete Response (CR)/Partial Response (PR)/Stable Disease (SD) will be followed for safety until 30 days from last dose intake (or until a new anticancer therapy starts, whichever occurs earlier) and will be assessed for efficacy in the follow-up period up to Day 180 from treatment start; - patients with progressive disease will be followed only for safety until 30 days from last dose intake (or until a new anticancer therapy starts, whichever occurs earlier). After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.

NCT ID: NCT03053596 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)

Start date: November 2016
Phase:
Study type: Observational

The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearls for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment.

NCT ID: NCT03006926 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma

Start date: February 15, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The Expansion part of the study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria In Solid Tumors (mRECIST) for HCC and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on independent imaging review (IIR).